Delivery Order SPE2DB20D2104-SPE2DB25FMWSA
- Not listed
- The Defense Logistics Agency awarded a $11,463.02 delivery order to AmerisourceBergen Drug Corp for 1,440 units/mL of HAVRIX vaccine syringes on July 28, 2025, with completion targeted for July 29, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,666.37 firm fixed price delivery order for 1,440 units of HAVRIX 1,440 Unit/mL syringe on April 18, 2025, with ultimate completion scheduled for April 21, 2025. This non-set-aside contract was competitively awarded to AmerisourceBergen's Corporate Office, with performance to occur at the company's Conshohocken, Pennsylvania headquarters. HAVRIX is a hepatitis A vaccine commonly utilized by the Department of Defense for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 1,440 units of HAVRIX 1,440 Unit/mL syringe on August 26, 2025, with a ceiling value of $2,017.25 and an ultimate completion date of August 27, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The contract represents a single transaction for the hepatitis A vaccine product, which will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,420.70 to AmerisourceBergen Drug Corp for the supply of Havrix 1,440 Unit/mL syringes. The contract, which was competitively awarded with no set-aside designation, carries an ultimate completion date of September 3, 2025, just one day after the award date of September 2, 2025. This delivery order operates under a firm fixed price arrangement and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,136.36 for 1,440 units/mL of HAVRIX vaccine syringes on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a single transaction under the company's larger pharmaceutical supply relationship...
- The Defense Logistics Agency awarded a delivery order valued at $10,140.60 to AmerisourceBergen Drug Corp for 1,440 units/mL of Havrix vaccine in syringe form. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure, with an ultimate completion date of July 21, 2025. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,012.20 to AmerisourceBergen Drug Corp for HAVRIX 720 Unit/0.5 ML syringes on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. HAVRIX is a hepatitis A vaccine product, reflecting the ongoing federal medical procurement needs for...
- The Defense Logistics Agency awarded a $1,234.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of HAVRIX 720 Unit/0.5 ML syringes. This is a non-set-aside competitive award with a completion date of September 3, 2025, and represents a direct fulfillment against AmerisourceBergen's existing pharmaceutical supply contract. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $1,613.80 to AmerisourceBergen Drug Corp for 1,440 units/mL of Havrix vaccine in syringe form. This is a firm fixed price, non-set-aside contract with an ultimate completion date of June 4, 2025, and represents a competitively awarded transaction. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the location of performance for this delivery order, which falls under the company's broader relationship with the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of 1,440 units of HAVRIX 1,440 Unit/mL syringes valued at $1,931.08. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The contract is scheduled for completion on September 9, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. HAVRIX is a hepatitis A...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMWSADelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 1,440 units of HAVRIX 1,440 unit/mL syringes valued at $2,311.38. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 30, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime vendor contract serves as a global pharmaceutical support vehicle enabling AmerisourceBergen to supply a comprehensive range of medications, vaccines, and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. AmerisourceBergen's consistent performance across multiple federal medical procurement requirements demonstrates its capability to meet stringent defense supply chain standards through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 7/29/25 |